ArticleInternational journal of women's health2026
Locally Advanced Invasive Mole in the Presence of Low Serum β-hCG: A Case Report.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive mole is one of the most common forms of gestational trophoblastic neoplasia (GTN), characterized by hydropic chorionic villi with trophoblastic proliferation invading the myometrium. Although it usually develops after complete hydatidiform mole, occurrence following partial hydatidiform mole is uncommon. Delayed follow-up and inadequate β-human chorionic gonadotropin (β-hCG) surveillance may contribute to disease progression and severe complications. Case Illustration: A 34-year-old woman para 2 abortus 1, presented with massive vaginal bleeding and hypovolemic shock six months after evacuation of a partial hydatidiform mole. Initial pre-evacuation β-hCG level was 1183002 mIU/mL. Due to financial constraints and inactive health insurance, post-evacuation follow-up was delayed. Serial β-hCG levels declined but remained persistently elevated for more than six months. The patient experienced continuous vaginal spotting and was diagnosed with stage I low-risk gestational trophoblastic neoplasia with a FIGO prognostic score of 4. Two weeks prior to the onset of massive bleeding, the patient had received the first cycle of single-agent methotrexate chemotherapy.Doppler ultrasonography demonstrated markedly increased myometrial vascularity suggestive of invasive mole. Despite blood transfusion, antifibrinolytic therapy, and initiation of single-agent methotrexate chemotherapy, severe vaginal bleeding persisted, resulting in profound anemia (hemoglobin 6.7 g/dL). Emergency total hysterectomy with bilateral salpingectomy was performed due to life-threatening hemorrhage. Histopathological examination confirmed invasive mole with trophoblastic invasion extending into the parametrium. No distant metastases were identified. Conclusion: Invasive mole following partial hydatidiform mole is rare but may lead to severe hemorrhagic complications when diagnosis and follow-up are delayed. Persistent elevation of β-hCG and abnormal uterine bleeding after molar evacuation should prompt early evaluation for gestational trophoblastic neoplasia. Multidisciplinary management, including chemotherapy, hemodynamic stabilization, and surgical intervention when indicated, is essential to achieve favorable outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.